{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:10:24Z","timestamp":1777993824031,"version":"3.51.4"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005725","name":"CHDI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.neuropharm.2017.12.033","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T07:52:41Z","timestamp":1513842761000},"page":"337-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Chronic paroxetine treatment prevents disruption of methamphetamine-sensitive circadian oscillator in a transgenic mouse model of Huntington's disease"],"prefix":"10.1016","volume":"131","author":[{"given":"Koliane","family":"Ouk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliet","family":"Aungier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Cuesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Jennifer","family":"Morton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.12.033_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1254\/jphs.FM0070121","article-title":"Neuropsychotoxicity of abused drugs: effects of serotonin receptor ligands on methamphetamine- and cocaine-induced behavioral sensitization in mice","volume":"106","author":"Ago","year":"2008","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib2","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/brain\/122.12.2353","article-title":"Huntington's disease progression. PET and clinical observations","volume":"122","author":"Andrews","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib3","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","article-title":"Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease","volume":"119","author":"Antonini","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archneur.65.4.482","article-title":"Rapid eye movement sleep disturbances in Huntington Disease","volume":"65","author":"Arnulf","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/1467-9450.00238","article-title":"Dopamine and cognitive functioning: brain imaging findings in Huntington's disease and normal aging","volume":"42","author":"B\u00e4ckman","year":"2001","journal-title":"Scand. J. Psychol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib6","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1093\/brain\/120.12.2207","article-title":"Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes","volume":"120","author":"B\u00e4ckman","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","article-title":"Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations","volume":"20","author":"Bernheimer","year":"1973","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib8","first-page":"1","article-title":"A\u00a0highly tunable dopaminergic oscillator generates ultradian rhythms of behavioral arousal","author":"Blum","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib9","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1152\/jn.00094.2012","article-title":"Methamphetamine produces bidirectional, concentration-dependent effects on dopamine neuron excitability and dopamine-mediated synaptic currents","volume":"108","author":"Branch","year":"2012","journal-title":"J.\u00a0Neurophysiol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0028-3908(02)00381-7","article-title":"Selective serotonin reuptake inhibitors enhance cocaine-induced locomotor activity and dopamine release in the nucleus accumbens","volume":"44","author":"Bubar","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib11","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1073\/pnas.95.11.6480","article-title":"Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene","volume":"95","author":"Cha","year":"1998","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fnins.2013.00114","article-title":"Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility","volume":"7","author":"Chen","year":"2013","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/1874473711205030227","article-title":"Mechanism of action of methamphetamine within the catecholamine and serotonin areas of the central nervous system","volume":"5","author":"Chiu","year":"2012","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib14","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.4049\/jimmunol.1000208","article-title":"Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease","volume":"185","author":"Chung","year":"2010","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bbr.2015.05.010","article-title":"Progression of behavioural despair in R6\/2 and Hdh knock-in mouse models recapitulates depression in Huntington's disease","volume":"291","author":"Ciamei","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.nbd.2011.07.016","article-title":"The methamphetamine-sensitive circadian oscillator is dysfunctional in a transgenic mouse model of Huntington's disease","volume":"45","author":"Cuesta","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib17","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.neuroscience.2005.05.012","article-title":"Effects of chronic paroxetine pretreatment on (\u00b1)-8-hydroxy-2-(di-n-propyl-amino)tetralin induced c-fos expression following sexual behavior","volume":"134","author":"de Jong","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib18","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ana.20075","article-title":"Paroxetine retards disease onset and progression in Huntingtin mutant mice","volume":"55","author":"Duan","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib19","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.nbd.2008.01.015","article-title":"Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease","volume":"30","author":"Duan","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0006-2952(93)90545-8","article-title":"Changes in monoamine oxidase activity in mouse brain associated with d-methamphetamine dependence and withdrawal","volume":"46","author":"Egashira","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib21","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/brain\/awt132","article-title":"Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6\/2 mouse model of Huntington's disease","volume":"136","author":"Fisher","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5665\/sleep.5448","article-title":"Quantitative EEG analysis provides an early-stage indicator of disease onset and progression in the zQ175 knock-in mouse model of Huntington's disease","volume":"39","author":"Fisher","year":"2016","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.brainresbull.2008.05.004","article-title":"Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice","volume":"77","author":"Fukushiro","year":"2008","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib24","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1176\/appi.ajp.159.10.1702","article-title":"Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine","volume":"159","author":"Gilmor","year":"2002","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib25","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/brain\/120.3.503","article-title":"PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease","volume":"120","author":"Ginovart","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib26","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1111\/j.1460-9568.2005.04365.x","article-title":"Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine","volume":"22","author":"Grote","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib27","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.25159","article-title":"Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease","volume":"27","author":"Guo","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib28","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbr.2013.08.045","article-title":"Animal models of the serotonin syndrome: a systematic review","volume":"256","author":"Haberzettl","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib29","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.cub.2008.04.012","article-title":"Regulation of monoamine oxidase A by circadian-clock components implies clock influence on mood","volume":"18","author":"Hampp","year":"2008","journal-title":"Curr. Biol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0197-0186(00)00043-7","article-title":"Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: an autoradiographic study","volume":"38","author":"H\u00e9bert","year":"2001","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1471-4159.2002.00804.x","article-title":"The role of dopamine in motor symptoms in the R6\/2 transgenic mouse model of Huntington's disease","volume":"81","author":"Hickey","year":"2002","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib32","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.brainres.2005.06.038","article-title":"Effects of continuous administration of paroxetine on ligand binding site and expression of serotonin transporter protein in mouse brain","volume":"1053","author":"Hirano","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0387-7604(86)80060-2","article-title":"Effects of methamphetamine on development of circadian rhythms in rats","volume":"8","author":"Honma","year":"1986","journal-title":"Brain Dev."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib34","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0031-9384(87)90281-2","article-title":"Activity rhythms in the circadian domain appear in suprachiasmatic nuclei lesioned rats given methamphetamine","volume":"40","author":"Honma","year":"1987","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib35","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0031-9384(86)90265-9","article-title":"Disorganization of the rat activity rhythm by chronic treatment with methamphetamine","volume":"38","author":"Honma","year":"1986","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/0748730407311124","article-title":"Circadian behavioral rhythms in Cry1\/Cry2 double-deficient mice induced by methamphetamine","volume":"23","author":"Honma","year":"2008","journal-title":"J.\u00a0Biol. Rhythm."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib37","doi-asserted-by":"crossref","first-page":"14046","DOI":"10.1523\/JNEUROSCI.2128-10.2010","article-title":"Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors","volume":"30","author":"Hood","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib38","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1046\/j.1460-9568.2002.02140.x","article-title":"Methamphetamine-induced, suprachiasmatic nucleus-independent circadian rhythms of activity and mPer gene expression in the striatum of the mouse","volume":"16","author":"Iijima","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neuroscience.2008.10.044","article-title":"Dopamine receptor-mediated regulation of neuronal \"clock\" gene expression","volume":"158","author":"Imbesi","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib40","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.neuroscience.2013.04.059","article-title":"Differential regulation of locomotor activity to acute and chronic cocaine administration by acid-sensing ion channel 1a and 2 in adult mice","volume":"246","author":"Jiang","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF03188784","article-title":"Functional and dispositional tolerance develops during continuous cocaine exposure","volume":"17","author":"Johansson","year":"1992","journal-title":"Eur. J. Drug Metab. Pharmokinet."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib42","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1471-4159.2006.03762.x","article-title":"Dopamine release is severely compromised in the R6\/2 mouse model of Huntington's disease","volume":"97","author":"Johnson","year":"2006","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib43","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.neuint.2007.08.015","article-title":"Perspectives on genetic animal models of serotonin toxicity","volume":"52","author":"Kalueff","year":"2008","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib99","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1093\/brain\/awt128","article-title":"Progressive sleep and electroencephalogram changes in mice carrying the Huntington's disease mutation","volume":"136","author":"Kantor","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib44","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s13311-017-0546-7","article-title":"Chronic paroxetine treatment prevents the emergence of abnormal electroencephalogram oscillations in Huntington's disease mice","volume":"14","author":"Kantor","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib45","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0091-3057(92)90664-2","article-title":"Intermittent and continuous cocaine administration: residual behavioral states during withdrawal","volume":"43","author":"King","year":"1992","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib46","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ana.410220318","article-title":"Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum","volume":"22","author":"Kish","year":"1987","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib47","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.npp.1300036","article-title":"Changes in human in\u00a0vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration","volume":"28","author":"Kugaya","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib48","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.neuropharm.2016.03.047","article-title":"The mood stabilizer valproic acid opposes the effects of dopamine on circadian rhythms","volume":"107","author":"Landgraf","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbr.2005.01.015","article-title":"Different effects of valproate on methamphetamine- and cocaine-induced behavioral sensitization in mice","volume":"161","author":"Li","year":"2005","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib50","doi-asserted-by":"crossref","first-page":"10428","DOI":"10.1523\/JNEUROSCI.19-23-10428.1999","article-title":"Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation","volume":"19","author":"Lione","year":"1999","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069993","article-title":"The Q175 mouse model of Huntington's Disease shows gene dosage- and age-related decline in circadian rhythms of activity and sleep","volume":"8","author":"Loh","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib52","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib53","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1046\/j.0953-816x.2001.01749.x","article-title":"Circadian activity rhythm in methamphetamine-treated Clock mutant mice","volume":"14","author":"Masubuchi","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib54","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/sj.npp.1300376","article-title":"Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential","volume":"29","author":"Maxwell","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib55","doi-asserted-by":"crossref","first-page":"9377","DOI":"10.1073\/pnas.0503584102","article-title":"Regulation of dopaminergic transmission and cocaine reward by the Clock gene","volume":"102","author":"McClung","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib56","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1176\/appi.ajp.158.1.78","article-title":"The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study","volume":"158","author":"Meyer","year":"2001","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib57","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0149-7634(94)90023-X","article-title":"Circadian food-anticipatory activity: formal models and physiological mechanisms","volume":"18","author":"Mistlberger","year":"1994","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018336","article-title":"Altered dopamine and serotonin metabolism in motorically asymptomatic R6\/2 mice","volume":"6","author":"Mochel","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib59","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1073\/pnas.0813366106","article-title":"The methamphetamine-sensitive circadian oscillator does not employ canonical clock genes","volume":"106","author":"Mohawk","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib60","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-neuro-060909-153128","article-title":"Central and peripheral circadian clocks in mammals","volume":"35","author":"Mohawk","year":"2012","journal-title":"Annu. Rev. Neurosci."},{"issue":"Suppl.\u00a03","key":"10.1016\/j.neuropharm.2017.12.033_bib61","first-page":"1","article-title":"Fast-onset antidepressants","volume":"12","author":"Montgomery","year":"1997","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib62","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.expneurol.2012.10.014","article-title":"Circadian and sleep disorder in Huntington's disease","volume":"243","author":"Morton","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib63","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.nbd.2008.11.015","article-title":"Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6\/2 mice","volume":"33","author":"Morton","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib64","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1023\/A:1010887421592","article-title":"Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation","volume":"29","author":"Morton","year":"2000","journal-title":"J.\u00a0Neurocytol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib65","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1523\/JNEUROSCI.3842-04.2005","article-title":"Disintegration of the sleep-wake cycle and circadian timing in Huntington's Disease","volume":"25","author":"Morton","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib66","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00210-001-0497-7","article-title":"Effect of paroxetine on extracellular serotonin and dopamine levels in the prefrontal cortex","volume":"365","author":"Nakayama","year":"2002","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib67","first-page":"77","article-title":"Paroxetine-the antidepressant from hell? Probably not, but caution required","volume":"46","author":"Nevels","year":"2016","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib68","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00213-007-0728-9","article-title":"Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test","volume":"192","author":"O'Leary","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib69","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.expneurol.2016.09.007","article-title":"Progressive gene dose-dependent disruption of the methamphetamine-sensitive circadian oscillator-driven rhythms in a knock-in mouse model of Huntington's disease","volume":"286","author":"Ouk","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib70","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/hmg\/ddn385","article-title":"Altered serotonin receptor expression is associated with depression-related behavior in the R6\/1 transgenic mouse model of Huntington's disease","volume":"18","author":"Pang","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib71","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0006-8993(93)90984-U","article-title":"Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in\u00a0vivo microdialysis","volume":"606","author":"Parsons","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib72","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1176\/jnp.17.4.496","article-title":"Depression and stages of Huntington's disease","volume":"17","author":"Paulsen","year":"2005","journal-title":"J.\u00a0Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib73","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1111\/ejn.12309","article-title":"The complex relationship between the light-entrainable and methamphetamine-sensitive circadian oscillators: evidence from behavioral studies of Period-mutant mice","volume":"38","author":"Pendergast","year":"2013","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib74","doi-asserted-by":"crossref","first-page":"14218","DOI":"10.1073\/pnas.1206213109","article-title":"Period determination in the food-entrainable and methamphetamine-sensitive circadian oscillator(s)","volume":"109","author":"Pendergast","year":"2012","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib75","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2007.10.015","article-title":"The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6\/2 Huntington's disease mouse model","volume":"210","author":"Peng","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib76","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.5665\/sleep.4996","article-title":"Polysomnographic findings and clinical correlates in Huntington Disease: a cross-sectional cohort study","volume":"38","author":"Piano","year":"2015","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib77","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/026988119801200404","article-title":"Psychopharmacological profile of the selective serotonin reuptake inhibitor, paroxetine: implication of noradrenergic and serotonergic mechanisms","volume":"12","author":"Redrobe","year":"1998","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib78","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0022-3565(25)39232-3","article-title":"Cocaine disposition in the brain after continuous or intermittent treatment and locomotor stimulation in mice","volume":"243","author":"Reith","year":"1987","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib79","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1476-5381.2011.01567.x","article-title":"Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise","volume":"165","author":"Renoir","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib80","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1046\/j.1471-4159.1999.721773.x","article-title":"Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation","volume":"72","author":"Reynolds","year":"1999","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib81","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10549-004-2175-1","article-title":"Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy","volume":"89","author":"Roscoe","year":"2005","journal-title":"Breast Canc. Res. Treat."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib82","doi-asserted-by":"crossref","first-page":"6406","DOI":"10.1073\/pnas.0609625104","article-title":"Mania-like behavior induced by disruption of CLOCK","volume":"104","author":"Roybal","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib83","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF02191583","article-title":"Dopamine D1 receptor number-a sensitive PET marker for early brain degeneration in Huntington's disease","volume":"243","author":"Sedvall","year":"1994","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib84","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0278-5846(01)00333-5","article-title":"Evaluation of the face validity of reserpine administration as an animal model of depression\u2013Parkinson\u2019s disease association","volume":"26","author":"Skalisz","year":"2002","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib85","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/JHD-160189","article-title":"Delayed onset and reduced cognitive deficits through pre-conditioning with 3-Nitropropionic Acid is dependent on sex and CAG Repeat Length in the R6\/2 mouse model of Huntington's disease","volume":"5","author":"Skillings","year":"2016","journal-title":"J.\u00a0Huntingtons. Dis"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib86","first-page":"119","article-title":"Norepinephrine and stimulant addiction","volume":"14","author":"Sofuoglu","year":"2009","journal-title":"Addict. Behav."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib87","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1111\/jcmm.12604","article-title":"Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6\/2 mouse model","volume":"19","author":"Squitieri","year":"2015","journal-title":"J.\u00a0Cell Mol. Med."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib88","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0014-2999(93)90073-Q","article-title":"Reduced levels of 5-HT3 receptor recognition sites in the putamen of patients with Huntington's disease","volume":"242","author":"Steward","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib89","first-page":"275","article-title":"Role of prefrontal serotonergic and dopaminergic systems in encounter-induced hyperactivity in methamphetamine-sensitized mice","volume":"58","author":"Tanaka","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib90","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nbd.2014.11.004","article-title":"Hyperactivation of D1 and A2A receptors contributes to cognitive dysfunction in Huntington's disease","volume":"74","author":"Tyebji","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib91","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/syn.890080405","article-title":"Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease","volume":"8","author":"Waeber","year":"1991","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib92","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ana.410400110","article-title":"Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease","volume":"40","author":"Weeks","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib93","first-page":"5","article-title":"Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of huntington's disease","author":"Wood","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib94","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molbrainres.2003.08.009","article-title":"Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology","volume":"119","author":"Yohrling","year":"2003","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib95","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1046\/j.1471-4159.2002.01084.x","article-title":"Inhibition of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington's disease","volume":"82","author":"Yohrling IV","year":"2002","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib96","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.1073\/pnas.0510691103","article-title":"Signaling mediated by the dopamine D2 receptor potentiates circadian regulation by CLOCK: BMAL1","volume":"103","author":"Yujnovsky","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2017.12.033_bib97","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1476-5381.1994.tb17087.x","article-title":"Role of 5-HT3 receptors in basal K+-evoked dopamine release from rat olfactory tubercule and striatal slices","volume":"113","author":"Zazpe","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.033_bib98","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF00437616","article-title":"Neuroleptic-induced deficits in food and water regulation: similarities to the lateral hypothalamic syndrome","volume":"43","author":"Zis","year":"1975","journal-title":"Psychopharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817306305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817306305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T03:25:22Z","timestamp":1751167522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817306305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":99,"alternative-id":["S0028390817306305"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.12.033","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic paroxetine treatment prevents disruption of methamphetamine-sensitive circadian oscillator in a transgenic mouse model of Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.12.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}